Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural Ulcer) - Pipeline Review, H1 2019, provides an overview of the Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline landscape.
Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural Ulcer) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural Ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural Ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Unknown stages are 2, 4, 1, 4 and 2 respectively.
Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural Ulcer) (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural Ulcer) (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Venous Leg Ulcers (Crural Ulcer) - Overview
Venous Leg Ulcers (Crural Ulcer) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Venous Leg Ulcers (Crural Ulcer) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Venous Leg Ulcers (Crural Ulcer) - Companies Involved in Therapeutics Development
CardioVascular BioTherapeutics Inc
CytoTools AG
Daval International Ltd
FirstString Research Inc
GangaGen Inc
MallInckrodt Plc
MediWound Ltd
NovaLead Pharma Pvt Ltd
Promore Pharma AB
Venous Leg Ulcers (Crural Ulcer) - Drug Profiles
Aimspro - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUP-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diperoxochloric acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBC-1013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EscharEx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LL-37 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLP-328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-42909 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products
Venous Leg Ulcers (Crural Ulcer) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2018: Promore Pharma has enrolled first patient in HEAL LL-37 in Poland
Sep 06, 2018: Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland
Aug 22, 2018: Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland
Jul 03, 2018: Promore Pharma receives approval for Phase IIb trial with LL-37
Oct 31, 2017: Promore Pharma Signs Agreement with CRO PCG Clinical Services
Sep 21, 2017: Promore Pharma Signs Manufacturing Agreement with APL
Sep 12, 2017: Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days
Sep 01, 2017: MediWound Successfully Completes Second Cohort of EscharEx Phase 2 Study
Jun 20, 2017: FirstString's President and CEO, Dr. Gautam Ghatnekar, Presents at the 2017 BIO International Convention in San Diego, CA
Jan 18, 2017: FirstString Research Wins Prestigious Tibbetts Award
Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results
Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers
Apr 19, 2013: Pergamum Reaches Last-Patient-Last-Visit In Phase I/II Trial Of LL-37 For Treatment Of Venous Leg Ulcers
Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Daval International Ltd, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by FirstString Research Inc, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Inc, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by MallInckrodt Plc, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, H1 2019
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products, H1 2019
List of Figures
Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
